31504-19-5

Usage

Chemical class

Purine derivative

Structure

Benzyl group attached to the 1-position and a pentofuranosyl group attached to the 9-position of the purine ring

Analog

Synthetic analog of adenosine

Biological and pharmacological activities

Studied for potential applications

Synthesis

Key intermediate in the synthesis of nucleoside analogs and other bioactive compounds

Significance

Important molecule in medicinal chemistry and drug development

Upstream product

• 100-44-7 benzyl chloride 
• 58-63-9 Inosine 
• 2016-04-8 N,N-dimethylformamide dibenzyl acetal 
• 58-63-9 inosine 
• 924887-45-6 1-(2,4-dinitrophenyl)inosine 
• 100-46-9 benzylamine 

Downstream Products

• 7074-59-1 1-benzyl-1,7⁽⁹⁾-dihydro-purin-6-one 
• 20735-74-4 5-amino-1-(β-D-ribofuranosyl)imidazole-4-(N-benzyl)carboxamide 
• 99236-81-4 Toluene-4-sulfonic acid (R)-2-(1-benzyl-6-oxo-1,6-dihydro-purin-9-yl)-2-[(S)-2-(tert-butyl-dimethyl-silanyloxy)-1-hydroxymethyl-ethoxy]-ethyl ester 
• 99236-80-3 1-Benzyl-9-{(S)-1-[(R)-2-(tert-butyl-dimethyl-silanyloxy)-1-hydroxymethyl-ethoxy]-2-hydroxy-ethyl}-1,9-dihydro-purin-6-one 
• 99236-82-5 1-benzyl-6-oxo-9-<(2R,6R)-6-tertbutyldimethylsilyloxymethyl-1-oxa-4-thiacyclohexane-2-yl>-9H-purine 
• 99051-98-6 1-benzyl-6-oxo-9-<(2R,6R)-6-hydroxymethyl-1-oxa-4-thiacyclohexan-2-yl>-9H-purine 
• 99236-78-9 1-benzyl-5'-O-tert-butyldimethysilylinosine 
• 7026-47-3 1-benzyl-2',3'-O-isopropylideneinosine 
• 2627-69-2 AICA riboside 

Relevant academic research and scientific papers

METHODS, COMPOSITIONS, AND FORMULATIONS FOR PREVENTING OR REDUCING ADVERSE EFFECTS IN A PATIENT

The present invention provides transdermal administration of AICA riboside, or a prodrugs, analogs, or salts thereof, and/or a blood clotting inhibitor for preventing or reducing adverse side effects in a patient. The type of patient that may benefit incl

Synthesis of 4-N-alkyl and ribose-modified AICAR analogues on solid support

Herein, we report the solid-phase synthesis of several 5-aminoimidazole-4-(N-alkyl)carboxamide-1-ribosides (4-N-alkyl AICARs) and the corresponding 2′,3′-secoriboside derivatives. The method uses the N-1-dinitrophenyl-inosine 5′-bonded to a solid support.

METHODS, COMPOSITIONS, AND FORMULATIONS FOR PREVENTING OR REDUCING ADVERSE EFFECTS IN A PATIENT

The present invention provides methods, compositions, formulations, and kits related to acadesine, or a prodrug, analog, or salt thereof, and/or a blood clotting inhibitor for preventing or reducing adverse side effects in a patient. The type of patient that may benefit includes a patient with decreased left ventricular function, a patient with a prior myocardial infarction, a patient undergoing non-vascular surgery, or a fetus during labor and delivery.

A Facile Synthesis of AICAR from Inosine

5-Amino-1-β-D-ribofuranosylimidazole-4-carboxamide (AICAR; 1) (Figure 1) was efficiently prepared from inosine through its 1-alkoxymethylderivatives. The stability of these derivatives enabled their purification by column chromatography (silica gel). The operation ensured the high quality of 1, which was obtained in good yield through alkaline hydrolysis of the derivatives.

Conformational restraint is a critical determinant of unnatural nucleotide recognition by protein kinases

This report describes the synthesis of N4-(benzyl) AICAR triphosphate, a conformationally restrained analogue of N4-(benzyl) ribavirin triphosphate. Both of these nucleotides were evaluated as phosphodonors for wild-type p38 MAP kina